Please assess the completion status of the following clinical trial:

Trial Title: A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HER2-positive disease determined locally~* Histologically or cytologically confirmed invasive breast cancer~* Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced or metastatic setting must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent~* Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy~* Measurable and/or non-measurable disease~* Left ventricular ejection fraction (LVEF) \>/=50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2~* Adequate organ function~* Use of highly effective contraception as defined by the protocol~Exclusion Criteria:~* History of treatment with trastuzumab emtansine~* Prior enrollment into a clinical study containing trastuzumab emtansine regardless of having received trastuzumab emtansine or not~* Peripheral neuropathy of Grade \>/= 3 per National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 4.0~* History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer~* History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to first study treatment except hormone therapy, which can be given up to 7 days prior to first study treatment; recovery of treatment-related toxicity consistent with other eligibility criteria~* History of exposure to cumulative doses of anthracyclines~* History of radiation therapy within 14 days of first study treatment. The participant must have recovered from any resulting acute toxicity (to Grade \</=1) prior to first study treatment.~* Metastatic central nervous system (CNS) disease only~* Brain metastases which are symptomatic~* History of a decrease in LVEF to less than (\<) 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment~* History of symptomatic CHF (New York Heart Association \[NYHA\] Classes II-IV) or serious cardiac arrhythmia requiring treatment~* History of myocardial infarction or unstable angina within 6 months of first study treatment~* Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy~* Current severe, uncontrolled systemic disease (clinically significant cardiovascular, pulmonary, or metabolic disease)~* Pregnancy or lactation~* Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus~* History of intolerance (such as Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any component of the product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Emtansine (All Participants) (Type: EXPERIMENTAL): This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
- Trastuzumab Emtansine (Asian Participants) (Type: EXPERIMENTAL): This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete